drugset / Trial / NCT02153671
Immunogenicity of H5N1 Vaccine Following H5N2
Phase 2
Completed
43 enrolled
PATH
Institute of Experimental Medicine, Russia · collabResearch Institute of Influenza, Russia · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This study is designed to assess whether a live attenuated Influenza vaccine (LAIV) can induce a long-lasting immune memory by comparing the immunologic response to two doses of the OrniFlu® inactivated vaccine given to subjects previously primed with LAIV and subjects who did not received LAIV.
Timeline
- Start
- 2014-05
- Primary completion
- 2014-09
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | A(H5N2) live attenuated influenza vaccine | Vaccine | — | — |
| Subject | OrniFlu | Vaccine | 0.5 ml | Intramuscular |
| Subject | OrniFlu | Vaccine | 15 mg | Intramuscular |
Indications
No indication recorded.